Key Takeaways
- Replimune secures $150 million financing for the commercial launch of TUDRIQEV, recently approved by the FDA.
- TUDRIQEV is set to be available in the U.S. within 60 days for patients with advanced cutaneous melanoma.
- The company is advancing its Phase 3 IGNYTE-3 study and reinforcing its commercial team ahead of the launch.
Replimune to Launch TUDRIQEV Following FDA Approval
Replimune has successfully completed a $150 million financing to prepare for the commercial launch of its drug TUDRIQEV, which received FDA accelerated approval on August 6. The treatment is indicated for adults with unresectable advanced cutaneous melanoma who have experienced disease progression following a PD-1 antibody-based regimen. The company expects TUDRIQEV to be available in the U.S. within 60 days post-approval.
This marked a significant transition for Replimune, shifting from a clinical-stage to a commercial-stage biotechnology company. The firm is actively building its commercial infrastructure as it gears up to introduce TUDRIQEV to healthcare providers and patients.
The recent financing attracted approximately $141 million in net proceeds through common stock issuance. This funding will support not only the commercial launch of TUDRIQEV but also ongoing expenditures, including the IGNYTE-3 confirmatory trial. As of June 30, Replimune had $195.3 million in cash and short-term investments. Despite a decline from $268.9 million at the end of March due to clinical development expenses, the company maintains a strong financial position with adequate resources to sustain its operations for over a year.
IGNYTE-3 is a global Phase 3 study actively enrolling participants to evaluate RP1 combined with nivolumab against a physician’s choice in patients with advanced melanoma who have progressed after anti-PD-1 and anti-CTLA-4 therapies. The primary endpoint is overall survival, with results projected for 2030. Secondary endpoints include progression-free survival and overall response rate. Confirmation of clinical benefit through this trial is essential, as continued approval of TUDRIQEV under the accelerated pathway depends on these outcomes.
Additionally, Replimune is advancing RP2 for metastatic uveal melanoma in its registration-directed REVEAL study, expected to transition into a Phase 2/3 trial in early 2027.
In preparation for the launch, Replimune has strengthened its commercial leadership by appointing Michelle DiNapoli as Chief Commercial Officer. DiNapoli brings over 25 years of biopharmaceutical experience, including leadership roles at Deciphera Pharmaceuticals and Genentech.
In its fiscal first quarter, Replimune reported a decline in R&D expenses to $49.3 million, down from $57.8 million a year prior, alongside decreased SG&A expenses of $19 million compared to $32.6 million. The company experienced a net loss of $69.8 million, an improvement from the $86.7 million loss in the same period last year.
Dr. Sushil Patel, CEO of Replimune, emphasized the significance of the FDA’s approval for both the company and patients facing advanced melanoma, underscoring their commitment to bringing effective treatment options to the market efficiently.
The content above is a summary. For more details, see the source article.